Rigel Pharmaceuticals (RIGL) Cash from Investing Activities (2010 - 2026)

Rigel Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$8.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 24.42% year-over-year to -$8.0 million; the TTM figure through Mar 2026 stood at -$89.8 million (down 1233.16% YoY), while the FY2025 annual figure was -$92.4 million, down 2336.44% from the prior year.
• Cash from Investing Activities was -$8.0 million for Q1 2026 at Rigel Pharmaceuticals, up from -$25.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $22.6 million in Q1 2022 to a low of -$33.2 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$1.6 million across 5 years, with a median of $313000.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities jumped 424.96% in 2024, then plunged 3471.25% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $18.6 million in 2022, then sank by 136.96% to -$6.9 million in 2023, then tumbled by 58.77% to -$10.9 million in 2024, then tumbled by 132.38% to -$25.4 million in 2025, then soared by 68.56% to -$8.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$8.0 million (Q1 2026), -$25.4 million (Q4 2025), and -$33.2 million (Q3 2025), per Business Quant data.